Canaccord lowered the firm’s price target on Zevra Therapeutics (ZVRA) to $23 from $25 and keeps a Buy rating on the shares. The firm ...

McFarlane, Zevra's President and Chief Executive Officer. "After years of tireless effort, our team has achieved a major milestone with FDA approval of MIPLYFFA™ (arimoclomol), and we're celebrating ...

Zevra’s MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty’s portfolio XOMA Royalty acquired a 50 percent economic interest in TWIST Bioscience’s ...

Zevra Therapeutics The U.S. Food and Drug Administration (FDA) approved Zevra’s MIPLYFFA™ (arimoclomol) capsules as an orally delivered treatment for Niemann-Pick disease type C (NPC).

Zevra’s MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty’s portfolio XOMA Royalty acquired a 50 percent economic ...

The FDA recently authorized two drugs, MIPLYFFA (arimoclomol) and AQNEURSA (levacetylleucine) that are supposed to help stop the symptoms or the progression of the rare disease. The approval is ...

In the third quarter, we reported net revenue of $3.7 million, which includes $2.6 million in net reimbursements from the French EAP for arimoclomol and $1.1 million of royalties and other ...

Zevra Therapeutics (NASDAQ:ZVRA) is scheduled to announce Q3 earnings results on Tuesday, November 12th, after market close.

The Emeryville, California-based company said it had a loss of $1.59 per share. Zevra’s MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty’s ...

Emrosi is expected to be available in the first quarter or early second quarter of 2025. The Food and Drug Administration has approved Emrosi ™ (minocycline hydrochloride extended-release ...

In cross-sectional analysis, children with asthma had lower scores on episodic memory, processing speed, inhibition, and attention. HealthDay News — Asthma is associated with memory difficulties ...